Literature DB >> 12859591

Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach.

Marianne L L van Genugten1, Rudolf T Hoogenveen, Ina Mulder, Henriëtte A Smit, Jan Jansen, Augustinus E M de Hollander.   

Abstract

OBJECTIVES: In this article, we explore the future health gain of different policy measures to reduce smoking prevalence: health education campaigns specifically aimed at keeping (young) people from starting to smoke, campaigns aimed at persuading smokers to quit, and tax measures.
METHODS: We drew up different policy scenarios based on evaluations of several health promotion campaigns. Implementing these into the dynamic multistate models, we simulated smoking prevalence, loss of life-years, and costs for several decades into the next century.
RESULTS: In the short run, campaigns aimed at potential "quitters" appear to be most effective in terms of health gain. However, their effect fades away after several decades, while campaigns aimed at young "starters" or tax measures in the end yield a larger and more lasting decrease in smoking attributable disease burden.
CONCLUSION: Dynamic modeling is very useful tool in calculating costs and effects of preventive public health measures.

Entities:  

Mesh:

Year:  2003        PMID: 12859591     DOI: 10.1046/j.1524-4733.2003.64157.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  4 in total

1.  Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity.

Authors:  Pieter H M van Baal; Rudolf T Hoogenveen; G Ardine de Wit; Hendriek C Boshuizen
Journal:  Popul Health Metr       Date:  2006-11-03

Review 2.  Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review.

Authors:  Marrit L Berg; Kei Long Cheung; Mickaël Hiligsmann; Silvia Evers; Reina J A de Kinderen; Puttarin Kulchaitanaroaj; Subhash Pokhrel
Journal:  Addiction       Date:  2017-02-15       Impact factor: 6.526

3.  Global economic cost of smoking-attributable diseases.

Authors:  Mark Goodchild; Nigar Nargis; Edouard Tursan d'Espaignet
Journal:  Tob Control       Date:  2017-01-30       Impact factor: 7.552

4.  Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation.

Authors:  Lieven Annemans; Sophie Marbaix; Kristiaan Nackaerts; Pierre Bartsch
Journal:  Prev Med Rep       Date:  2015-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.